Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
RESEARCH TOOLSreports
Bicycle Therapeutics (BCYC) Stock Price & Analysis
302 Followers
BCYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.54 - $28.91
Previous Close$23.45
Volume168.62K
Average Volume (3M)398.34K
Market Cap
$975.93M
Enterprise Value$508.70M
Total Cash (Recent Filing)$526.40M
Total Debt (Recent Filing)$40.08M
Price to Earnings (P/E)-4.6
Beta1.17
Next Earnings
May 02, 2024EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.15
Shares Outstanding42,586,185
10 Day Avg. Volume413,669
30 Day Avg. Volume398,342
Standard Deviation0.19
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.69
Price to Sales (P/S)32.93
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.86
Enterprise Value/Gross Profit18.86
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$44.71Price Target Upside94.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bicycle Therapeutics News
PremiumCompany Announcements
Bicycle Therapeutics Announces Board Reshuffle and New Financial Agreement
PremiumCompany Announcements
Bicycle Therapeutics Welcomes Stephen Sands to Board
Bulls Say, Bears Say
Bulls Say
Clinical Trials And SafetyImproved safety profile for BT8009 compared to competitors could lead to better patient treatment compliance and market acceptance, bolstering Bicycle Therapeutics' position in the market.
Drug Discovery And PipelineBicycle Therapeutics' broad capabilities of its drug discovery platform and potential future pipeline programs present an attractive opportunity.
Financial HealthA strong cash position suggests Bicycle Therapeutics has a solid financial foundation to support its operations and advance its product candidates.
Bears Say
Competitive PositionDespite early promising results, BT8009 has a lower objective response rate compared to the competing treatment in combination therapy.
Financial PerformanceResearch & Development expenses exceeded estimates, which could indicate higher costs than expected in the development of their products.
Product PipelineThe anticipated launches of BT8009, BT1718 and BT5528 have been delayed.
---
Ownership Overview
52.11% Insiders
5.95% Mutual Funds
1.04% Other Institutional Investors
40.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Bicycle Therapeutics Ltd lowest stock price was $12.54 and its highest was $28.91 in the past 12 months.
What is Bicycle Therapeutics Ltd’s market cap?
Currently, no data Available
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is May 02, 2024 which is in 9 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on Feb 20, 2024. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.233 by $0.073.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -$1.25.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Bicycle Therapeutics Ltd has 37,967,346 shares outstanding.
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.233. Following the earnings report the stock price went up 0.844%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Among the largest hedge funds holding Bicycle Therapeutics Ltd’s share is Baker Bros Advisors LP. It holds Bicycle Therapeutics Ltd’s shares valued at 32M.
---
Bicycle Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.71 (94.39% Upside)
$44.71 (94.39% Upside)
Blogger Sentiment
Bullish
BCYC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 627.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
-56.50%
Trailing 12-Months
Asset Growth
44.99%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
---
BCYC Stock 12 Months Forecast
Average Price Target
$44.71
▲(94.39% Upside)
Technical Analysis
Best Analysts Covering BCYC
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+43.34%
reiterated a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +43.34% per trade.
---